John T. Blake

Chief Financial Officer at Second Sight Medical Products, Inc.

John T. Blake

John T. Blake

Chief Financial Officer at Second Sight Medical Products, Inc.

Overview
Career Highlights

Second Sight Medical Products, Inc.
aTyr Pharma, Inc.

RelSci Relationships

234

Birthday

1976

Age

42

Relationships
RelSci Relationships are individuals John T. Blake likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Second Sight Medical Products, Inc.

Relationship likelihood: Strong

Co-Founder at Versant Venture Management LLC

Relationship likelihood: Strong

Former President & Chief Executive Officer at Second Sight Medical Products, Inc.

Relationship likelihood: Strong

Founder at ForSight Labs LLC

Relationship likelihood: Strong

Chief Project Engineer at Second Sight Medical Products, Inc.

Relationship likelihood: Strong

Vice President & General Manager EMEA & Asia Pacific at Second Sight Medical Products, Inc.

Relationship likelihood: Strong

Head of Marketing at Second Sight Medical Products, Inc.

Relationship likelihood: Strong

Director at Second Sight Medical Products, Inc.

Relationship likelihood: Average

Director of Product Development at Second Sight Medical Products, Inc.

Relationship likelihood: Average

Co-Founder at REPLIGEN Corp.

Relationship likelihood: Average

Paths to John T. Blake
Potential Connections via
Relationship Science
You
John T. Blake
Chief Financial Officer at Second Sight Medical Products, Inc.
Education

Since 1971, National University has been dedicated to making lifelong learning opportunities accessible, challenging, and relevant to a diverse student population. As a nonprofit institution, National University invests in its students by providing them with quality educational instruction and learning technologies, superior faculty, and exemplary student services.

Career History
Chief Financial Officer
2018 - Current

Second Sight Medical Products, Inc. creates a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as Retinitis Pigmentosa. It develops, manufactures and market implantable visual prosthetics to enable blind individuals to overcome disability and achieve greater independence. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Dr. Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Senior Vice President, Chief Financial & Accounting Officer
2015 - 2018

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.

Director-Financial Planning & Analysis
2007 - 2015

Volcano Corporation develops, manufactures and commercializes a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The Company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab and single use disposable imaging catheters unique to our system. Our IVUS offerings are used by clinicians to measure the stage and severity of disease present in cardiac and peripheral vessels. IVUS is also used in post-stent placement procedures to confirm adequate expansion of the stent and full apposition to the vessel wall. Volcano IVUS offers unique features, including both phased array and rotational IVUS imaging catheters and advanced functionality options, such as VH® IVUS tissue characterization, ChromaFlo® and FFR (fractional flow reserve) technology. Volcano also provides functional management (FM) consoles and single-use pressure and flow guide wires, which are used to gauge the impact of arterial plaque on blood flow and pressure. The Company is also developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters, Forward Looking IVUS (FLIVUS) catheters and other image-guided therapy products. Currently, more than 3,900 Volcano s5/s5i IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States

Transactions
Details Hidden

aTyr Pharma, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations